Intrapulmonary IFN-β gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8379-8387

  Wilderman, Michael J ^a   Sun, Jing ^a   Jassar, Arminder S ^a   Kapoor, Veena ^a   Khan, Mohamed ^a   Vachani, Anil ^a   Suzuki, Eiji ^a   Kinniry, Paul A ^a   Sterman, Daniel H ^a   Kaiser, Larry R ^a   Albelda, Steven M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Thoracic Oncology Research Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; BETA INTERFERON; CRE RECOMBINASE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL KILLING; CONTROLLED STUDY; GENE ACTIVATION; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOGENE K RAS; PLAQUE FORMING CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR IMMUNITY; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CARCINOMA, BRONCHOGENIC; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENES, RAS; INTERFERON-BETA; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MUTATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 24944521057     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0920     Document Type: Article

References (46)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Lengyel P. Biochemistry of interferons and their actions. Annu Rev Biochem 1982;51:251-82.
3. Biron CA. Role of early cytokines, including α and β interferons (IFN-α/β), in innate and adaptive immune responses to viral infections. Semin Immunol 1998;10:383-90.
4. Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J. Interferon-β induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 1997;17:355-67.
5. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489-99.
6. Sen GC, Lengyel P. The interferon system. A bird's eye view of its biochemistry. J Biol Chem 1992;267:5017-20.
7. Brem H, Gresser I, Grosfeld J, Folkman J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 1993;28:1253-7.
8. Xu L, Xie K, Fidler IJ. Therapy of human ovarian cancer by transfection with the murine Interferon β gene: role of macrophage-inducible nitric oxide synthase. Hum Gene Ther 1998;9:2699-708.
9. Cao G, Su J, Lu W, et al. Adenovirus-mediated interferon-β gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 2001;8:497-505.
10. Izawa JI, Sweeney P, Perrotte P, et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-β gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 2002;8:1258-70.
11. Sakurai F, Terada T, Maruyama M, et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-β gene and poly I:poly C in a murine lung metastasis model. Cancer Gene Ther 2003;10:661-8.
12. Qin XQ, Tao N, Dergay A, et al. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci U S A 1998;95:14411-6.
13. Lu W, Fidler IJ, Dong Z. Eradication of primary murine fibrosarcomas and induction of systemic immunity by adenovirus-mediated interferon β gene therapy. Cancer Res 1999;59:5202-8.
14. Natsume A, Mizuno M, Ryuke Y, Yoshida J. Antitumor effect and cellular immunity activation by murine interferon-β gene transfer against intracerebral glioma in mouse. Gene Ther 1999;6:1626-33.
15. Nakanishi H, Mizutani Y, Kawauchi A, et al. Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-β gene against human renal cell carcinoma. Clin Cancer Res 2003;9:1129-35.
16. Nakahara N, Pollack IF, Storkus WJ, et al. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-β gene vector and dendritic cells. Cancer Gene Ther 2003;10:549-58.
17. Tada H, Maron DJ, Choi EA, et al. Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 2001;108:83-95.
18. Odaka M, Sterman DH, Wiewrodt R, et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity. Cancer Res 2001;61:6201-12.
19. Odaka M, Wiewrodt R, DeLong P, et al. Analysis of the immunologic response generated by Ad IFN-β during successful intraperitoneal tumor gene therapy. Mol Ther 2002;6:210-8.
20. DeLong P, Tanaka T, Kruklitis R, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003;63:7845-52.
21. Tuveson DA, Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene 1999;18:5318-24.
22. Tuveson DA, Jacks T. Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 2002;12:105-10.
23. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-8.
24. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996;7:1555-66.
25. Jooss K, Turka LA, Wilson JM. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther 1998;5:309-19.
26. Kolb M, Inman M, Margetts PJ, Gait T, Gauldie J. Budesonide enhances repeated gene transfer and expression in the lung with adenoviral vectors. Am J Respir Crit Care Med 2001;164:866-72.
27. Chirmule N, Raper SE, Burkly L, et al. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions. J Virol 2000;74:3345-52.
28. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111-6.
29. Fasbender A, Lee JH, Walters RW, et al. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J Clin Invest 1998;102:184-93.
30. Winn HJ. In vivo methods for the assessment of antibody-mediated tumor immunity. J Natl Cancer Inst Monogr 1972;35:13-8.
31. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220.
32. Lokshin A, Mayotte JE, Levitt ML. Mechanism of interferon β-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines. J Natl Cancer Inst 1995;87:206-12.
33. Belhumeur P, Lanoix J, Blais Y, et al. Action of spontaneously produced β interferon in differentiation of embryonal carcinoma cells through an autoinduction mechanism. Mol Cell Biol 1993;13:2846-57.
34. Orange JS, Biron CA. Characterization of early IL-12, IFN-αβ, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J Immunol 1996;156:4746-56.
35. Fujihara M, Ito N, Pace JL, et al. Role of endogenous interferon-β in lipopolysaccharide-triggered activation of the inducible nitric-oxide synthase gene in a mouse macrophage cell line, J774. J Biol Chem 1994;269:12773-8.
36. Xie K, Bielenberg D, Huang S, et al. Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with the murine IFN-β gene: possible role of nitric oxide. Clin Cancer Res 1997;3:2283-94.
37. Spear GT, Paulnock DM, Jordan RL, et al. Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo β-interferon. Clin Exp Immunol 1987;69:107-15.
38. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I Interferon in vivo. Science 1996;272:1947-50.
39. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999;189:521-30.
40. Singh RK, Gutman M, Bucana CD, et al. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562-6.
41. Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J. IFN-β gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 2000;47:117-24.
42. Marchetti A, Buttitta F, Pellegrini S, et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 1996;179:254-9.
43. Mason RJ, Kalina M, Nielsen LD, Malkinson AM, Shannon JM. Surfactant protein C expression in urethane-induced murine pulmonary tumors. Am J Pathol 2000;156:175-82.
44. Wikenheiser KA, Whitsett JA. Tumor progression and cellular differentiation of pulmonary adenocarcinomas in SV40 large T antigen transgenic mice. Am J Respir Cell Mol Biol 1997;16:713-23.
45. Tursz T, Cesne AL, Baldeyrou P, et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996;88:1857-63.
46. Gahery-Segard H, Molinier-Frenkel V, Le Boulaire C, et al. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest 1997;100:2218-26.